Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide
On September 3, 2024, Eli Lilly filed a complaint against the FDA in the District Court for the Southern District of Indiana pursuing the latest challenge to the FDA’s application of its “biological product” classification. See… more